Enthusiasm abounds in today’s biologics industry for continuous biomanufacturing. Although intensification of single unit operations using semicontinuous processing strategies remains much more common than implementation of fully integrated upstream and downstream processes, the latter model is no longer merely theoretical. Researchers already have demonstrated proof of concept for continuous monoclonal antibody (mAb) manufacturing at pilot scale, and some service providers have begun offering fully integrated manufacturing capabilities. At least in new facilities, broad adoption of continuous capabilities could be just around the corner. Amid that climate of excitement, continuous chromatography is ripe for innovation and implementation, especially considering downstream purification’s historical status as the primary bottleneck in mAb manufacturing.
In this eBook, BPI’s managing editor speaks with John P. Rubero (senior fellow of downstream bioprocessing at facilities design and engineering firm CRB) about what continuous chromatography approaches are currently available for protein purification. Rubero describes what methods scientists might expect to find in different parts of the biopharmaceutical industry and explores what equipment formats, facility needs, and operational complexities might accompany such methods. He also explores the future of continuous chromatography, highlighting technical needs and heralding new developments that could help manufacturers to reap the benefits of continuous purification.
Register or Login and hit Download to get the full eBook.